Chosa Oncology AbNGM: CHOSA

CHOSA Oncology in connection with the TO2 warrant exercise

· Issued by Chosa Oncology Ab

CHOSA Oncology’s CCO and board member Claus Frisenberg Pedersen visits Västra Hamnen and discusses the latest developments, what benefit CHOSA brings to cancer patients and how the company creates shareholder value. CHOSA is exercising its TO2 warrants during the period July 1 – 14, the subscription price is 0.78 SEK per share. The interview is moderated by Västra Hamnen’s chief analyst Martin Dominique.

Watch the video here.

About Market Focus

The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.

This is a press release from Västra Hamnen Corporate Finance AB.

Web: vhcorp.se

Twitter: @vhcorp_se (https://x.com/vhcorp_se)

Earlier from Chosa Oncology Ab

All Chosa Oncology Ab news releases